Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Authors' conclusion
Bimagrumab effectively reversed adverse effects on body composition in obese individuals, resulting in significant fat reduction, increased skeletal muscle mass, and improved glycemic control
Study context
- Population
- Adults with obesity, insulin resistance or T2D
- Participants
- 268 adults4 randomized controlled trials (RCTs)
- Comparison
- Bimagrumab vs placebo
- Outcome
- Efficacy on body composition and glucose parameters, and safety
Methodological detailsRoB 2 risk of bias assessment, Grades of Recommendation, Assessment, Development, and Evaluation (GRADE), Searched MEDLINE, PubMed, Embase, Cochrane Library on April 20, 2026
- RoB 2 risk of bias assessment
- GRADE
- Searched MEDLINE, PubMed, Embase, Cochrane Library on April 20, 2026
Pooled result
As reported in the abstract
Each group vs placeboEstimate (95% CI)
Bimagrumab
MD (total weight) −4.85 kg(−6.82 to −2.88)
Bimagrumab
MD (fat mass) −4.72 kg(−8.05 to −1.40)
Bimagrumab
MD (total lean mass) 1.66 kg(0.81–2.51)
Each group vs placeboMD (HbA1c), % (95% CI)
Bimagrumab
−0.13(−0.23 to −0.03)
Safety
| Outcome | Increase (mmol/L) (CI) | |
|---|---|---|
| LDL concentration | 0.47 (0.03–0.91) | |
| −0.500.51Difference, mmol/L (linear scale) |
| Outcome | Estimate | |
|---|---|---|
| Discontinuation, muscle spasms, diarrhoeaBimagrumabvs Placebo | RR (discontinuation) 5.75 (CI 1.61–20.46) | |
| Discontinuation, muscle spasms, diarrhoeaBimagrumabvs Placebo | RR (muscle spasms) 10.44 (CI 4.23–25.75) | |
| Discontinuation, muscle spasms, diarrhoeaBimagrumabvs Placebo | RR (diarrhoea) 4.91 (CI 2.38–10.11) | |
| 0.050.21520Ratio (log scale) |
Original publication
Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Diabetes Obes Metab. Published 30 July 2026. doi:10. 1111/ dom. 71156
Composed by AI from the published abstract and checked against it. How Briefs are made →